SCHEMBL8909335

SCHEMBL8909335

O=C(OC1CCNCC1)N1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 2/20 0.48
TPSD1 Q9BZJ3 2/20 0.48
TPSG1 Q9NRR2 2/20 0.48
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.43
HRH3 Q9Y5N1 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 2/20 0.41
KDM1A O60341 1/20 0.40
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8266944 0.87 TSHR (0.55) TP53TSHRHRH3SMN1; SMN2USP2
SCHEMBL17479229 0.85 TPSAB1 (0.52) TPSAB1TPSD1TPSG1KDM1A
SCHEMBL28067576 0.84 TPSAB1 (0.55) TPSAB1TPSD1TPSG1KDM1A
SCHEMBL26124912 0.84 TPSAB1 (0.55) TPSAB1TPSD1TPSG1KDM1A
SCHEMBL31512292 0.84 L3MBTL1 (0.51) TPSAB1TPSD1TPSG1TP53TSHR
SCHEMBL12162946 0.84 HRH3 (0.51) TPSAB1TPSD1TPSG1TP53TSHR
SCHEMBL18505995 0.82 TSHR (0.46) TP53TSHRHRH3SMN1; SMN2USP2
SCHEMBL5623295 0.82 L3MBTL1 (0.54) TPSAB1TPSD1TPSG1TP53TSHR
SCHEMBL9363422 0.81 TPSAB1 (0.41) TPSAB1TPSD1TPSG1TP53TSHR
SCHEMBL4283947 0.79 TPSAB1 (0.51) TPSAB1TPSD1TPSG1HRH3KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3063148-B1 AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2020-04-29 EP disclosed
EP-3063148-B1 AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2020-04-29 EP disclosed
EP-3063148-A1 AZABENZIMIDAZOLE DERIVATIVES Boehringer Ingelheim International GmbH (DE) 2016-09-07 EP disclosed
US-9187477-B2 Azabenzimidazole derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-11-17 US disclosed
US-9187477-B2 Azabenzimidazole derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-11-17 US disclosed
US-9187477-B2 Azabenzimidazole derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-11-17 US disclosed
WO-2015063011-A1 AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-05-07 WO disclosed
WO-2015063011-A1 AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-05-07 WO disclosed
US-20150119393-A1 NEW AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-30 US disclosed
US-20150119393-A1 NEW AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-30 US disclosed
US-20150119393-A1 NEW AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-30 US disclosed
EP-0684948-B1 MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME DIAGNOSTIKFORSCHUNG INST (DE) 1997-10-22 EP disclosed
EP-0684948-A1 MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME. DIAGNOSTIKFORSCHUNG INST (DE) 1995-12-06 EP disclosed
WO-1994019352-A1 MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) 1994-09-01 WO disclosed
EP-0447013-B1 Fluorobenzene sulphonamides SCHERING AG (DE) 1994-08-03 EP disclosed
EP-0263059-B1 COMPLEXES AMIDES SCHERING AKTIENGESELLSCHAFT (DE) 1992-11-11 EP disclosed
EP-0447013-A1 Fluorobenzene sulphonamides SCHERING AKTIENGESELLSCHAFT (DE) 1991-09-18 EP disclosed
EP-0413405-A2 Use of amide complex compounds SCHERING AKTIENGESELLSCHAFT (DE) 1991-02-20 EP disclosed
EP-0336879-A1 Meso-tetraphenylporphyrin complex compounds,process for their preparation and pharmaceuticals containing them SCHERING AKTIENGESELLSCHAFT (DE) 1989-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119393-A1 NEW AZABENZIMIDAZOLE DERIVATIVES PRKAR2B, PRKAB2, PRKAB1 TPSAB1 2957/4885TPSD1 3820/4885TPSG1 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.